ProCE Banner Activity

QuANTUM-R: Phase III Trial of Quizartinib in Patients With FLT3-ITD–Mutated Relapsed/Refractory AML

Slideset Download
Conference Coverage
In patients with R/R FLT3-ITD–mutated AML, single-agent quizartinib significantly prolongs survival compared with salvage chemotherapy with a low incidence of grade 3 QT prolongation.

Released: December 17, 2018

Expiration: December 16, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology